INTRODUCTION: Dexmedetomidine is an alpha-2 agonist used for conscious sedation. It has also been shown to have a myocardial protective effect in off-pump coronary artery bypass patients. The aim of the study was to assess the effect of dexmedetomidine for myocardial protection in percutaneous coronary interventional patients. METHODOLOGY: A total of 60 patients (group dexmedetomidine, n = 30 and group normal saline, n = 30) were enrolled in the study. Dexmedetomidine infusion (1 mcg/kg) over 15 min was given as a loading dose after coronary angiography in group dexmedetomidine (D) while normal saline was given in the control group (C) and later maintenance infusion was started at 0.5 mcg/kg/h in both the groups. Coronary vessel diameter was noted before (T0) and after (T1) loading dose of dexmedetomidine/saline in each group. Troponin T (Trop T) values were noted at baseline (T0), 6 h (T2), 12 h (T3) and 24 h (T4) after starting the loading dose. Hemodynamic variables (heart rate [HR] and blood pressure) were monitored at T0, T1, and at regular intervals till 2 h postprocedure. RESULTS: Coronary vessel diameter and HR significantly decreased in group D as compared to control group (P < 0.05) whereas the decrease in Trop T at 6 h, 12 h, and 24 h were not statistically significant between the two groups. CONCLUSION: Dexmedetomidine decreases the coronary vessel diameter, but maintains the myocardial oxygen demand-supply ratio by decreasing the HR. The decrease in Trop T is statistically insignificant at the doses used.
INTRODUCTION:Dexmedetomidine is an alpha-2 agonist used for conscious sedation. It has also been shown to have a myocardial protective effect in off-pump coronary artery bypass patients. The aim of the study was to assess the effect of dexmedetomidine for myocardial protection in percutaneous coronary interventional patients. METHODOLOGY: A total of 60 patients (group dexmedetomidine, n = 30 and group normal saline, n = 30) were enrolled in the study. Dexmedetomidine infusion (1 mcg/kg) over 15 min was given as a loading dose after coronary angiography in group dexmedetomidine (D) while normal saline was given in the control group (C) and later maintenance infusion was started at 0.5 mcg/kg/h in both the groups. Coronary vessel diameter was noted before (T0) and after (T1) loading dose of dexmedetomidine/saline in each group. Troponin T (Trop T) values were noted at baseline (T0), 6 h (T2), 12 h (T3) and 24 h (T4) after starting the loading dose. Hemodynamic variables (heart rate [HR] and blood pressure) were monitored at T0, T1, and at regular intervals till 2 h postprocedure. RESULTS: Coronary vessel diameter and HR significantly decreased in group D as compared to control group (P < 0.05) whereas the decrease in Trop T at 6 h, 12 h, and 24 h were not statistically significant between the two groups. CONCLUSION:Dexmedetomidine decreases the coronary vessel diameter, but maintains the myocardial oxygen demand-supply ratio by decreasing the HR. The decrease in Trop T is statistically insignificant at the doses used.
Authors: Jani Penttilä; Antti Helminen; Markku Anttila; Susanna Hinkka; Harry Scheinin Journal: Can J Physiol Pharmacol Date: 2004-05 Impact factor: 2.273
Authors: J Jalonen; M Hynynen; A Kuitunen; H Heikkilä; J Perttilä; M Salmenperä; M Valtonen; R Aantaa; A Kallio Journal: Anesthesiology Date: 1997-02 Impact factor: 7.892
Authors: H D White; R M Norris; M A Brown; M Takayama; A Maslowski; N M Bass; J A Ormiston; T Whitlock Journal: N Engl J Med Date: 1987-10-01 Impact factor: 91.245
Authors: M L Simoons; P W Serruys; M van den Brand; J Res; F W Verheugt; X H Krauss; W J Remme; F Bär; C de Zwaan; A van der Laarse Journal: J Am Coll Cardiol Date: 1986-04 Impact factor: 24.094
Authors: F H Sheehan; R Doerr; W G Schmidt; E L Bolson; R Uebis; R von Essen; S Effert; H T Dodge Journal: J Am Coll Cardiol Date: 1988-08 Impact factor: 24.094
Authors: Gülay Kip; Ali Çelik; Mustafa Bilge; Metin Alkan; Hasan Ali Kiraz; Abdullah Özer; Volkan Şıvgın; Özlem Erdem; Mustafa Arslan; Mustafa Kavutçu Journal: Libyan J Med Date: 2015-09-18 Impact factor: 1.743